PepGen Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $217.2M
- Price
- $3.14
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.46%
- Volume
- 672.2K
About
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Quick stats
Shares outstanding69.2M
Computed float39.8M
Float / shares57.5%
Cash runway (months)17.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001835597
Websitehttps://www.pepgen.com
AI Summary
AI-generated1/25
majorbullishearnings
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen reported Q2 2026 financial results, highlighting a net loss of $0.26 per share and a cash position of $117.2 million, which funds operations into Q4 2027.
Clinically, the DSMB recommended advancing the FREEDOM2 trial to the 12.5 mg/kg cohort and escalating the OLE study dose to 10 mg/kg, citing positive safety data.
The 10 mg/kg cohort is fully enrolled with data expected in November, while results from the higher dose cohort are anticipated in the first half of 2027.